Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Acarbose vs Pioglitazone (Actos): they're closely matched on evidence (4 vs 4/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Acarbose and Pioglitazone (Actos) are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Acarbose and Pioglitazone (Actos) have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing: taken with the first bite of carbohydrate-containing meals, titrated from a low dose (e.g. 25 mg) up to 50–100 mg per meal as GI tolerance allows. A prescription drug, not an approved longevity regimen.
with-meals
Oral tablet with meals
Off-label metabolic use mirrors diabetes dosing (e.g. 15–45 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (pioglitazone)
Unknown in humans
Years
Per meal
With each carb-containing meal
Weeks to months
Months to years
Months
Throughout use
Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.
Aging cell (2016) · Animal
NIA ITP study: acarbose extended lifespan, most strongly in male genetically heterogeneous mice
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Diabetologia (2004) · Rct · n=1429
STOP-NIDDM randomized trial in impaired-glucose-tolerance adults
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA (2003) · Rct
Randomized analysis of acarbose and cardiovascular/hypertension risk
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
The New England journal of medicine (2016) · Rct · n=3876
IRIS randomized trial in patients with insulin resistance but no diabetes after recent stroke/TIA (n=3,876)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet (London, England) (2005) · Rct · n=5238
PROactive randomized trial in high-cardiovascular-risk type 2 diabetics (n=5,238)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Annals of internal medicine (2016) · Rct
Randomized, placebo-controlled trial of long-term pioglitazone in NASH with prediabetes/type 2 diabetes
Both Acarbose and Pioglitazone (Actos) are closely matched — the best choice depends on your specific health goals.
For manage blood sugar, Pioglitazone (Actos) has a higher relevance score (62 vs 60).
No known interactions between Acarbose and Pioglitazone (Actos) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.